- Home
- ORIC vs CRGX Comparison
ORIC vs CRGX Comparison
Compare ORIC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- CRGX
- Stock Information
- Founded
- ORIC 2014
- CRGX 2021
- Country
- ORIC United States
- CRGX United States
- Employees
- ORIC N/A
- CRGX N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- ORIC Health Care
- CRGX
- Exchange
- ORIC Nasdaq
- CRGX Nasdaq
- Market Cap
- ORIC 735.3M
- CRGX 628.6M
- IPO Year
- ORIC 2020
- CRGX 2023
- Fundamental
- Price
- ORIC $10.84
- CRGX $3.70
- Analyst Decision
- ORIC Strong Buy
- CRGX Hold
- Analyst Count
- ORIC 9
- CRGX 7
- Target Price
- ORIC $18.75
- CRGX $4.67
- AVG Volume (30 Days)
- ORIC 825.1K
- CRGX 1.9M
- Earning Date
- ORIC 03-10-2025
- CRGX 03-20-2025
- Dividend Yield
- ORIC N/A
- CRGX N/A
- EPS Growth
- ORIC N/A
- CRGX N/A
- EPS
- ORIC N/A
- CRGX N/A
- Revenue
- ORIC N/A
- CRGX N/A
- Revenue This Year
- ORIC N/A
- CRGX N/A
- Revenue Next Year
- ORIC N/A
- CRGX N/A
- P/E Ratio
- ORIC N/A
- CRGX N/A
- Revenue Growth
- ORIC N/A
- CRGX N/A
- 52 Week Low
- ORIC $6.33
- CRGX $3.00
- 52 Week High
- ORIC $16.65
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- ORIC 52.90
- CRGX 20.88
- Support Level
- ORIC $9.92
- CRGX $3.00
- Resistance Level
- ORIC $12.00
- CRGX $3.88
- Average True Range (ATR)
- ORIC 0.90
- CRGX 0.92
- MACD
- ORIC 0.04
- CRGX -1.00
- Stochastic Oscillator
- ORIC 41.82
- CRGX 5.99
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.